Skip to main

Blood supply and the purpose of repair

Blood-vessel research around KLOW peptide

I started with circulation as a supporting detail. The vessel experiments deserve a larger role: they change the question from general repair to a particular vascular response.

Vessel width in the BPC-157 experiments

The 2020 BPC-157 vascular study examined rat vasculature and endothelial models. It connected altered vascular tone with the Src–Caveolin-1–eNOS pathway. The last part is an enzyme involved in producing nitric oxide, a signal associated with vessel relaxation.

The current of interest here is a change in an existing vessel’s behaviour. The paper also reported widening that persisted despite a chemical used to inhibit nitric-oxide production. I would resist making that into a reassuring claim that BPC-157 automatically corrects circulation. The experimental result gives a reason to investigate how the response occurs; the medical claim would require evidence about people and the condition being treated.

KLOW peptide was absent from this experiment. The other ingredients could change the result, contribute nothing useful, or introduce difficulties. Those possibilities remain open.

A technician adjusts the supports of a glass vessel-testing bath at a bright laboratory bench
Illustrative laboratory scene showing the kind of apparatus used to study vessel tension; it does not depict the study’s actual laboratory.

VEGF and new vessel growth

With full-length thymosin beta-4, cell experiments found increased expression of VEGF. That finding concerns a signal for forming vessels. Pairing blood supply with tissue repair sounds attractive to me. The interesting test would measure whether that signal produces useful vascular changes and a useful outcome in the same setting.

A separate rat wound experiment with full-length thymosin beta-4 did measure repair. Compared with saline, re-epithelialization—the skin covering the wound—rose 42% at 4 days and up to 61% at 7 days. Wound contraction increased at least 11% by day 7, alongside increased collagen deposition and angiogenesis.

Those findings belong to the full protein. TB-500 is a shorter fragment. Substituting the fragment in a blend introduces another experimental question before any result can be credited to KLOW.

Copper-binding fragments from SPARC

One of the more unusual sources in this literature starts with a tissue protein being broken down. Proteolysis of SPARC released copper-binding peptides, including GHK and KGHK, that stimulated angiogenesis in endothelial-cell and animal assays. KGHK was the most potent in that work, and the activity did not depend on prior copper binding.

I had expected breakdown to end a signal. Here it releases active fragments. It complicates the neat picture of repair as simply adding more material. It also calls for restraint with names: this study examined a family of fragments and their activity, rather than demonstrating a clinical vascular benefit from the GHK-Cu in KLOW.

Tendon recovery and the proposed combination

The BPC-157 study in rats with fully transected Achilles tendons reported better biomechanics, function and collagen organisation. Cultured rat tendon cells also showed increased outgrowth. These outcomes make the repair interest understandable. They still leave the vascular mechanism and the final tissue result as separate things to establish for a mixture.

An experiment connecting the vascular changes to the same injury outcome, and comparing the complete blend with its components, could make this argument persuasive. At present, the literature offers separate experiments across different tissues, species and preparations. That collection cannot establish whether adding KPV and GHK-Cu to BPC-157 and TB-500 improves an injured person’s recovery.

The 2026 Sports Medicine review of peptide therapies describes favourable animal findings alongside scarce rigorous human safety data and potential serious harm. That is the clinical gap the vascular detail must eventually meet.